Arbutus Biopharma (ABUS) vs Ironwood Pharmaceuticals (IRWD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Ironwood Pharmaceuticals (IRWD) has outperformed Arbutus Biopharma (ABUS) over the past year, gaining 146.7% versus a gain of 0.0%. Over five years, ABUS leads with a +5.1% price change compared with -72.5% for IRWD. Arbutus Biopharma is the larger company by market cap ($657.6 million vs $619.6 million), about 1.1 times the size.
On valuation, Ironwood Pharmaceuticals trades at a lower trailing P/E (4.9x vs 5.4x for Arbutus Biopharma).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | IRWD |
|---|---|---|
| Share price | $4.29 | $3.75 |
| Market cap | $657.55M | $619.65M |
| 1-day change | -4.24% | +3.31% |
| YTD return | -10.81% | +11.28% |
| 1-year return | 0.00% | +146.71% |
| 5-year return | +5.15% | -72.55% |
| P/E ratio (TTM) | 5.43 | 4.87 |
| Forward P/E | — | 2.50 |
| EPS (TTM) | $0.79 | $0.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.45 | $5.78 |
| 52-week low | $3.50 | $1.41 |
| Distance from 52-week high | -21.28% | -35.12% |
| Analyst consensus | none | none |
| Avg. price target upside | +24.71% | +62.67% |
| Average volume | 4.68M | 2.03M |
| Shares outstanding | 153.28M | 165.24M |
| Employees | 19 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRWD has outperformed ABUS by 146.7 percentage points over the past year.
About Arbutus Biopharma
ABUS stock →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Ironwood Pharmaceuticals
IRWD stock →Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
ABUS vs IRWD FAQ
Which is bigger, Arbutus Biopharma or Ironwood Pharmaceuticals?
Arbutus Biopharma (ABUS) is larger, with a market capitalization of $657.55M compared with $619.65M for Ironwood Pharmaceuticals (IRWD).
Which stock has performed better over the past year, ABUS or IRWD?
IRWD returned +146.71% over the past 12 months, compared with 0.00% for ABUS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ABUS or IRWD?
IRWD has the lower trailing P/E at 4.9, versus 5.4 for ABUS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Arbutus Biopharma and Ironwood Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.